Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive #ProstateCancer #PSMAddition. Presented by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @RKSayyid @UAUrology > https://t.co/7zXJ29P3we @myESMO

What is next after clinical trials testing PSMA & lutetium-177? Presentation by @CalaisJeremie @UCLA. #ESMO25 written coverage by @chavarriagaj @UofT > https://t.co/iGAkHOZFSW @myESMO

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? "Tumor sequestration affects 68Ga-PSMA biodistribution in normal organs. Patients with a very high tumor load showed a significantly lower uptake of 68Ga-PSMA in normal organs, confirming a tumor sink effect. " An

Evaluation of PSMA PET/CT derived predictors for treatment response to 177Lu-PSMA-617: Results from The U.S. Expanded-Access Program. Presented by Koichiro Kimura, MD @UCLA. #SNMMI25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/lq7rX7C9pR #SNMMI2025 @SNM_MI

@SNMMI25 Dr Andrew Scott gave Henry Wagner lecture and honored Dr Saul Hertz as founder I-131 therapy and the beginning of our Industrial Revolution now occuring in radiopharmaceutical development and theranostics

How about Lead-212? Presentation by David Pattison, MBBS, MPH, FRACP, highlighting 212Pb as a promising alpha-emitter for PSMA-targeted therapy in #mCRPC—offering potent tumor kill, short-range precision, manageable safety, and even immune activation potential.. #SNMMI25 written

. @GEHealthCare Unveils Enhanced LesionID Pro at #SNMMI25 Conference https://t.co/S3eJCOGhHp @RadiologyACR @ARRS_Radiology @RSNA @SNM_MI @YaleRadiology @PennRadiology @Hopkins_Rad @OSURadiology @UABRadiology @WinshipAtEmory @MontefioreRAD #radiology #RadRes

Huge congratulations to @DrMHofman for receiving the prestigious 2025 @TheRACP Eric Sussman Prize, presented for the best contribution to the knowledge of any branch of internal medicine, adult or pediatrics, for his work in prostate theranostics. https://t.co/6aaxmECgZl

The 63rd Annual Meeting of the German Society for Nuclear Medicine (Deutsche Gesellschaft für Nuklearmedizine - DGN) kicked off yesterday in Bremen! 🇩🇪 If you're attending, stop by the EANM desk! 👋

@DrMHofman presents at 2025 PSMA & Beyond Conference @UCLA @UCSF @PCFnews ... Impressive attendance! Thanks to organisers: @thomashopemd @CalaisJeremie @CzerninJohannes @urotoday Don't miss our next webinar: https://t.co/zABXXv5CYP

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: https://t.co/rFs5M8lO6v

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication https://t.co/WWcggKLvaD The @US_FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer (mCRPC)

Lot of content, Great Presentations and discussions during these 2 days ! Thank you all !! @CalaisJeremie @thomashopemd @PCF_Science @UCLA @UCSF @urotoday @CzerninJohannes

WHAT A FLIGHT! On our first flight today we got to a clean liftoff, 30sec of flight, and didn't blow up the pad in the meantime. Super proud of our team @isaraerospace

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the @PSMAconference!

Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. @RO_GreenJournal @masatoshihotta @UCLA https://t.co/nOhMUVc9J0

Looking forward to seeing everyone at the @PSMAconference starting Friday at UCLA. We have sold out all of our in person availability! If you haven’t registered, you can still join virtually ( https://t.co/cdNjDsoXJI).

ONE WEEK until the 2025 PSMA & Beyond Conference! Space is limited so register soon! If you cannot join us in LA, virtual registration is available for only $50! https://t.co/wwnKQsNCPx

PSMA PET must be used for clinical trial readouts and by regulators. Is PCWG4 coming? Mike Morris will tell us if and how!

Response and progression criteria for PSMA PET: Imaging #ProstateCancer outcomes. Wolfgang Fendler, MD @unidue joins Oliver Sartor, MD @MayoClinic, to discuss the evolving role of PSMA PET imaging in assessing treatment response and progression in prostate cancer. #WatchNow >